Universe Pharmaceuticals (Universe Pharmaceuticals) ROE % : -25.15% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Universe Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Universe Pharmaceuticals's annualized net income for the quarter that ended in Sep. 2023 was $-10.90 Mil. Universe Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Sep. 2023 was $43.33 Mil. Therefore, Universe Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2023 was -25.15%.

The historical rank and industry rank for Universe Pharmaceuticals's ROE % or its related term are showing as below:

UPC' s ROE % Range Over the Past 10 Years
Min: -16.58 Med: 36.97 Max: 78.53
Current: -13.89

During the past 6 years, Universe Pharmaceuticals's highest ROE % was 78.53%. The lowest was -16.58%. And the median was 36.97%.

UPC's ROE % is ranked worse than
75% of 996 companies
in the Drug Manufacturers industry
Industry Median: 4.225 vs UPC: -13.89

Universe Pharmaceuticals ROE % Historical Data

The historical data trend for Universe Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universe Pharmaceuticals ROE % Chart

Universe Pharmaceuticals Annual Data

Trend

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROE %

Get a 7-Day Free Trial

68.44

45.55

28.39

-16.58

-14.34

Universe Pharmaceuticals Semi-Annual Data
	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROE %	Get a 7-Day Free Trial						15.22	5.77	-38.91	-3.06	-25.15

Competitive Comparison of Universe Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universe Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Universe Pharmaceuticals's ROE % falls into.

Universe Pharmaceuticals ROE % Calculation

Universe Pharmaceuticals's annualized ROE % for the fiscal year that ended in Sep. 2023 is calculated as

ROE %	=	Net Income (A: Sep. 2023 )	/	( (Total Stockholders Equity (A: Sep. 2022 )	+	Total Stockholders Equity (A: Sep. 2023 ))	/ count )
	=	-6.163	/	( (46.442	+	39.533)	/ 2 )
	=	-6.163	/	42.9875
	=	-14.34 %

Universe Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2023 is calculated as

ROE %	=	Net Income (Q: Sep. 2023 )	/	( (Total Stockholders Equity (Q: Mar. 2023 )	+	Total Stockholders Equity (Q: Sep. 2023 ))	/ count )
	=	-10.896	/	( (47.127	+	39.533)	/ 2 )
	=	-10.896	/	43.33
	=	-25.15 %

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Sep. 2023) net income data. ROE % is displayed in the 30-year financial page.

Universe Pharmaceuticals (NAS:UPC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

	ROE %		(Q: Sep. 2023 )
=	Net Income	/	Total Stockholders Equity
=	-10.896	/	43.33
=	(Net Income / Revenue )	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-10.896 / 27.684)	*	(27.684 / 61.8275)	*	(61.8275 / 43.33)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-39.36 %	*	0.4478	*	1.4269
=	ROA %	*	Equity Multiplier
=	-17.63 %	*	1.4269
=	-25.15 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

	ROE %		(Q: Sep. 2023 )
=	Net Income	/	Total Stockholders Equity
=	-10.896	/	43.33
=	(Net Income / Pre-Tax Income)	*	(Pre-Tax Income / Operating Income)	*	(Operating Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-10.896 / -8.218)	*	(-8.218 / -8.23)	*	(-8.23 / 27.684)	*	(27.684 / 61.8275)	*	(61.8275 / 43.33)
=	Tax Burden	*	Interest Burden	*	Operating Margin %	*	Asset Turnover	*	Equity Multiplier
=	1.3259	*	0.9985	*	-29.73 %	*	0.4478	*	1.4269
=	-25.15 %

Note: The net income data used here is two times the semi-annual (Sep. 2023) net income data. The Revenue data used here is two times the semi-annual (Sep. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
^* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Universe Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Universe Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Universe Pharmaceuticals (Universe Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Universe Pharmaceuticals Inc (NAS:UPC) » Definitions » ROE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

265 Jingjiu Avenue, Economic & Technological Development Zone, Jinggangshan, Jiangxi, Ji’an, CHN

Website

http://www.universe-pharmacy.com

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.